AxoGen (NASDAQ:AXGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

AxoGen (NASDAQ:AXGN) had its price target lifted by investment analysts at Canaccord Genuity Group from $50.00 to $55.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. Canaccord Genuity Group’s price objective indicates a potential upside of 30.32% from the company’s previous close.

AXGN has been the subject of several other research reports. Wells Fargo & Company raised their target price on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Lake Street Capital boosted their target price on shares of AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Citigroup reaffirmed a “market outperform” rating on shares of AxoGen in a report on Thursday. Finally, Raymond James Financial reissued an “outperform” rating and set a $48.00 price target on shares of AxoGen in a report on Wednesday, April 29th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, AxoGen presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

AxoGen Stock Performance

NASDAQ:AXGN traded up $0.83 during trading hours on Thursday, reaching $42.20. 528,132 shares of the stock were exchanged, compared to its average volume of 1,118,135. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $2.24 billion, a P/E ratio of -66.01 and a beta of 1.09. The firm has a 50 day simple moving average of $42.10 and a 200-day simple moving average of $37.28. AxoGen has a 52 week low of $12.39 and a 52 week high of $46.95.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The business had revenue of $69.73 million for the quarter, compared to the consensus estimate of $67.10 million. As a group, sell-side analysts forecast that AxoGen will post -0.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Amy Mcbride Wendell sold 1,647 shares of AxoGen stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $42.60, for a total value of $70,162.20. Following the completion of the transaction, the director directly owned 93,826 shares of the company’s stock, valued at $3,996,987.60. The trade was a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John Johnson sold 11,050 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $43.26, for a total transaction of $478,023.00. Following the transaction, the director owned 11,050 shares in the company, valued at approximately $478,023. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 29,041 shares of company stock valued at $1,268,792. 2.44% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AxoGen

Institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC grew its stake in shares of AxoGen by 1.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 21,473 shares of the medical equipment provider’s stock valued at $703,000 after purchasing an additional 371 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of AxoGen by 6.2% during the first quarter. PNC Financial Services Group Inc. now owns 8,943 shares of the medical equipment provider’s stock valued at $296,000 after acquiring an additional 525 shares during the period. Arax Advisory Partners boosted its holdings in AxoGen by 362.4% in the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 819 shares during the last quarter. Brooklyn Investment Group lifted its stake in shares of AxoGen by 4.2% in the 4th quarter. Brooklyn Investment Group now owns 20,568 shares of the medical equipment provider’s stock valued at $688,000 after purchasing an additional 823 shares during the period. Finally, MCF Advisors LLC bought a new stake in shares of AxoGen during the 4th quarter worth approximately $30,000. 80.29% of the stock is owned by institutional investors.

AxoGen News Summary

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: AxoGen reported second-quarter revenue of $69.73 million, above the $67.10 million analyst estimate. Earnings were $0.12 per share; this matched the broader consensus cited by MarketBeat and exceeded the $0.09 Zacks consensus estimate. AxoGen Second Quarter 2026 Financial Results
• Positive Sentiment: The earnings coverage highlighted continued strong revenue growth, supporting the investment case for AxoGen’s peripheral nerve repair products and helping drive the favorable stock reaction. AxoGen Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Management updated its fiscal 2026 earnings guidance, but the available report does not provide the revised figures, limiting the ability to assess whether the outlook improved or weakened. AxoGen Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the revenue and adjusted-EPS performance, AxoGen continues to face margin pressure. The company reported a negative net margin of 13.21% and negative return on equity, while analysts expect a full-year loss of approximately $0.37 per share. AxoGen Q2 2026 Earnings

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.